DURHAM, N.C.–(BUSINESS WIRE)– Recent research has shed light on the predictability of fractures that
fail to heal, known as nonunions. All nonunions are a function of
severity, location and disease comorbidity and while risk factor
interaction is complex, a new study reports that it may become possible
to predict nonunion based on the patient-specific presentation of risk
factors. The findings are published in the September 7, 2016 issue of JAMA
Surgery available at http://archsurg.jamanetwork.com/article.aspx?articleid=2547685.
The study found that in 2011, among 309,330 fractures in 18 bones, the
overall nonunion rate was 4.93%. However, higher nonunion risk was
associated with severe fractures, high body mass index, smoking and
alcoholism. While females had more fractures, males were more prone to
nonunion. In addition, the risk of nonunion increased for patients who
used certain medications including antibiotics, anticoagulants, and
opioids, as well as for patients who had diseases such as obesity,
osteoarthritis and osteoporosis.
“We hypothesized that the interplay between a patient’s physiological
risk factors and fracture characteristics increased the risk of fracture
nonunion,” said Dr. R. Grant Steen, Manager of Medical Affairs,
Bioventus. “We now believe clinicians can use this information to
describe the epidemiology of fracture nonunion in adult patients.”
The study was funded by Bioventus and used fracture patients from a
health plan database. Patients with fracture were identified and
continuous enrollment in the database was required for 12 months after
fracture, to allow sufficient time to capture a nonunion diagnosis.
Authors of this study include Robert Zura, MD, LSU Health Science
Center, New Orleans, Ze Xiong, MS, Dept. of Statistics, North Carolina
State University, Thomas Einhorn, MD, NYU Langone Medical Center, J.
Tracy Watson, MD Saint Louis University School of Medicine, Robert F.
Ostrum, MD University of North Carolina, Michael J. Payson, MD, Wright
State University, Gregory J. Della Rocca, MD, PhD, University of
Missouri, Samir Mehta, MD, Hospital of the University of Pennsylvania,
Todd McKinley, MD, Indiana University, Zhe Wang, MS, Dept. of
Statistics, North Carolina State University and R. Grant Steen, PhD,
Manager of Medical Affairs, Bioventus.
Bioventus is an orthobiologics company that delivers clinically proven,
cost-effective products that help people heal quickly and safely. Its
mission is to make a difference by helping patients resume and enjoy
active lives. Bioventus has two product portfolios for orthobiologics,
Bioventus Active Healing Therapies and Bioventus Surgical that make it a
global leader in active orthopaedic healing. Built on a commitment to
high quality standards, evidence-based medicine and strong ethical
behavior, Bioventus is a trusted partner for physicians worldwide.
Bioventus and the Bioventus logo are registered trademarks of Bioventus
Thomas Hill, 919-474-6715